Surgery Godfather-Chapter 1971 - 1342: The Tide of Worldly Affairs

Shortly after Li Gaoyang delivered his speech, he reached out to Huang Jiacai from Ruixing, hoping to arrange a meeting with Huang Jiacai and Professor Yang’s team members, a request that Yang Ping agreed to.

Singapore, the top-floor suite of Marina Bay Sands Hotel.

The meeting was not held in a conference room but in a private living room, with only six participants: Huang Jiacai, a lawyer brought by Tang Shunhe, and three from the other side—Li Gaoyang, his chief strategist Elena Chen, and a discreet legal advisor.

No media, no assistants, not even hotel service staff; the tea was prepared by Elena herself.

"Mr. Huang, Dr. Tang, thank you very much for agreeing to meet." Li Gaoyang took the initiative to extend his hand, his handshake firm and steady, with a rosy complexion that completely belied his past as a terminal patient, "I am Li Gaoyang, and this is Elena Chen, my strategy lead. This is David Lee, our legal advisor, responsible for the compliance section of this cooperation framework."

After the handshake, they skipped the small talk and went straight to the point.

"I watched your video." Huang Jiacai sat on the sofa, looking calmly at Li Gaoyang, "It was candid, powerful. But I have a few questions to confirm."

"Please go ahead." Li Gaoyang leaned forward slightly, showing his focus.

"First, you personally benefited from K Therapy. Does this impact your and your giant group’s business judgment? Or, to what extent is this collaboration proposal based on personal gratitude versus the group’s long-term strategy?"

The question was sharp, aiming straight at the core motivation.

Li Gaoyang didn’t hesitate for a moment: "Both are involved, but strategic consideration dominates. Without the lure of strategic benefits, no matter how much I personally advocate, the board would not pass my resolution. Mr. Huang, I’ve been running this company for over fifteen years; I’ve witnessed too many waves of technology. From monoclonal antibodies to immune checkpoint inhibitors, to gene editing. Every time, the real winners were not the resistors but the earliest adopters and leaders."

He motioned Elena to turn on the tablet, projecting a set of data onto the wall screen.

"This is the analysis our internal research department did over the past three years." The screen displayed complex curves and models, "Traditional targeted drug development costs an average of 2.6 billion dollars, takes 12 years, and has a success rate of less than 10%. Moreover, with the increasing complexity of diseases and the emergence of drug resistance, the marginal benefits of this path are declining rapidly."

The screen switched, showing the logical framework diagram of the system regulation theory.

"System regulation, on the other hand, offers a completely different approach: instead of attacking a single target, it restores the system’s self-regulation ability. This means, once the core principles and tools are mastered, we can address a wider range of diseases, including those complex chronic and rare diseases that traditional methods are helpless against, at a lower cost and faster speed. K Therapy is a successful application case of system regulation theory."

Li Gaoyang’s eyes lit up, not with the gratitude of a patient towards a life-saving benefactor, but with the excitement of a top entrepreneur seeing a blue ocean market.

"From a business perspective, this is a paradigm shift. Resisting it would be like Kodak resisting digital photography, or Nokia resisting Android. Embracing it, however, could make us the ’Apple’ or ’Tesla’ of the new era. My personal experience only allowed me to realize this earlier and more profoundly, giving me extra determination and persuasion to drive change," he admitted.

Huang Jiacai nodded slightly.

"Second," Huang Jiacai continued to ask, "Regarding the comprehensive cooperation you mentioned, can you specify what it entails? What does the giant group hope to gain, and what are they willing to offer?"

This time Elena Chen responded. She was an Asian woman in her forties, with sharp eyes and a very quick speech.

"Mr. Huang, we envision a phased, multidimensional strategic alliance." She pulled up another detailed framework chart, "Phase one: deep technical integration and clinical implementation. We seek complete authorization and joint development rights for system regulation therapy in major global markets, but not through a simple buy-sell transaction. We propose to establish a joint research center, with the location designated by you, while funding, equipment, and operations are provided by us. The direction of research and leadership will rest with your team."

"Phase two: the establishment of a system medicine education system. We are willing to invest in establishing the ’International Systems Medicine Research Institute,’ collaborating with your Sanbo Research Institute, Professor Manstein, and other international partners to formulate global certification standards and train doctors and researchers. This is not only a public good but also cultivates the talent ecosystem for the future market."

"Phase three: co-development and commercialization of new therapies. Based on system regulation theory, we intend to develop new therapies for major diseases beyond tumors, such as Alzheimer’s disease, metabolic syndrome, and autoimmune diseases. Intellectual property rights will be shared, and commercialization profits will be divided according to agreed proportions. We can provide a global network for clinical trials, regulatory filing experience, and market channels."

She paused, looking at Huang Jiacai and Tang Shun: "As for what we are willing to offer, aside from the aforementioned funds, resources, and channels, the most important element is: an open stance and industry influence. We will leverage our voices in industry associations, regulatory dialogues, and international forums to fully support the scientific position of system regulation theory. We will openly share our past ’imitation failure’ attempts data, proving the irreplaceability of the complete theoretical system. We will help establish a reasonable regulatory framework rather than contest it."